Engineering bacterium for preparing difucosyllactose and application thereof
By providing new glycosyltransferases SAMT and fut3Bc and constructing an efficient engineering strain CS-10, the problem of insufficient difucosyl lactose synthetase in the prior art is solved, and efficient and low-cost DFL production is achieved. The output reached 53.15g/L.
Patent Information
- Application Number
- CN202411193285.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-29
AI Technical Summary
In the prior art, difucosyl lactose (DFL) has limited number of synthesases, insufficient catalytic capacity and adaptability, resulting in high production costs and low production capacity.
Provided ɑ-1,2-glycosyltransferase SAMT and ɑ-1,3-glycosyltransferase fut3Bc. Through the synergistic action of these enzymes, the synthesis capacity of difucosyl lactose is improved and efficient The engineered strain CS-10 knocked out some genes, enhanced the expression of specific enzymes, and achieved high yield DFL synthesis.
The production of difucosyl lactose was significantly increased to 53.15g/L, exceeding the production capacity of the existing technology and reducing production costs.
Smart Images

Figure CN119040413A_ABST
Abstract
Description
Technical Field
[0001] The present application relates to the technical field of microbial metabolic engineering, and in particular to an engineering bacterium for preparing difucosyllactose and its application. Background Art
[0002] Human milk oligosaccharides (HMOs) are polysaccharides found in breast milk that have received great attention in recent years due to their probiotic and immunomodulatory properties. They can be roughly divided into three categories: fucosylated, neutral, and sialylated HMOs. In addition, the HMOs composition of breast milk also varies between lactating mothers, which is intricately related to the secretory (Se) and Lewis (Le) blood group antigens. According to statistics, about 61% of the oligosaccharides in breast milk are fucosylated HMOs, among which 2′-fucosyllactose (2′-FL, 31%), 3-fucosyllactose (3-FL, 5%), LNFP I (8%), LNDFHI (4%), and difucosyllactose (DFL, 4%) are the most abundant fucosylated HMOs. DFL (Fuc-α1,2-Gal-β1,4-(Fuc-α1,3-)Glc) is an α-1,2 / 3-fucosylated HMO, usually modified with 2′-FL or 3-FL as the backbone. Interestingly, the slight difference in the structure of DFL compared to 2′-FL and 3-FL has a strong antimicrobial activity against Streptococcus agalactiae, a pathogen that causes neonatal sepsis. However, 2′-FL and 3-FL are completely inactive against S. agalactiae. But DFL can reduce the number of inflammatory molecules by preventing platelet aggregation and activation. In addition, DFL has been shown to promote intestinal health by selectively promoting the colonization of Bifidobacteria. So far, DFL has been approved and authorized as a new food additive by the European Food Safety Authority (ESPA) and the US Food and Drug Administration (FDA).
[0003] Currently, DFL can be produced by chemical, enzymatic and catalytic synthesis and microbial fermentation. The chemical synthesis of DFL involves complex production conditions and rigorous and cumbersome steps, and the cost of raw materials is high; although enzymatic synthesis is mild and controllable, and the target product can be obtained quickly, the production cost is high due to the high price of synthetic precursors. In contrast, metabolic engineering strategies provide high-performance methods for the synthesis of DFL, including de novo synthesis and salvage pathway synthesis.
[0004] In the production process of DFL, the dual enzymes of α-1,2-fucosyltransferase and α-1,3-glycosyltransferase are required for coordinated in vivo catalysis, which places higher demands on the in vivo coordination and specificity of the enzymes. However, the number of enzymes reported for DFL synthesis is limited. According to the prior art, patents CN118064340A and
[0005] CN117925492A uses FucT2 and Hp3 / 4FT from Helicobacter pylori to achieve de novo synthesis of DFL through protein engineering and metabolic engineering technologies, and the production capacity is in the range of 30-50 g / L. In addition, no other glycosyltransferases with strong catalytic ability and good adaptability that can be used for the synthesis of DFL have been found. Summary of the invention
[0006] To solve the above problems, the purpose of the present invention is to provide two new glycosyltransferases, which have the ability to efficiently synthesize difucosyllactose, and on this basis, provide a difucosyllactose-synthesizing engineered bacterium with strong catalytic ability, good adaptability and higher production capacity.
[0007] On the one hand, the present application provides the use of ɑ-1,2-glycosyltransferase and / or ɑ-1,3-glycosyltransferase in preparing difucosyllactose (DFL) and / or increasing the yield of difucosyllactose, wherein the ɑ-1,2-glycosyltransferase is SAMT and the ɑ-1,3-glycosyltransferase is fut3Bc.
[0008] In a preferred embodiment, the SAMT is derived from Azospirillum lipoferum.
[0009] In a preferred embodiment, the fut3Bc is derived from Neobacillus cucumis.
[0010] Further, the amino acid sequence of SAMT includes SEQ ID NO.11 or an amino acid sequence having at least 98% identity with SEQ ID NO.11; preferably, the nucleotide sequence encoding SAMT includes SEQ ID NO.1 or a nucleotide sequence having at least 98% identity with SEQ ID NO.1;
[0011] And / or, the amino acid of fut3Bc includes SEQ ID NO.12 or an amino acid sequence having at least 98% identity with SEQ ID NO.12; preferably, the nucleotide sequence encoding fut3Bc is SEQ ID NO.2 or a nucleotide sequence having at least 98% identity with SEQ ID NO.2.
[0012] Preferably, the amino acid sequence of SAMT comprises SEQ ID NO.11 or an amino acid sequence having at least 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with SEQ ID NO.11.
[0013] Preferably, the nucleotide sequence encoding SAMT comprises SEQ ID NO.1 or a nucleotide sequence having at least 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identity with SEQ ID NO.1.
[0014] Preferably, the amino acids of fut3Bc include SEQ ID NO.12 or an amino acid sequence that is at least 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to SEQ ID NO.12.
[0015] Preferably, the nucleotide sequence encoding fut3Bc is SEQ ID NO.2 or a nucleotide sequence having at least 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identity with SEQ ID NO.2.
[0016] In this application, SAMT and fut3Bc were used for the first time to synthesize DFL using lactose as a substrate, providing two new enzymes and a new enzyme combination for the synthesis of DFL, and providing new ideas for the transformation of DFL-related engineering bacteria.
[0017] On the other hand, the present application also provides a biomaterial, wherein the biomaterial is related to the above-mentioned α-1,2-glycosyltransferase and / or α-1,3-glycosyltransferase, and the biomaterial comprises any one of the following:
[0018] B1) the biological material comprises a cDNA nucleic acid molecule or a DNA nucleic acid molecule of SEQ ID NO.1 and / or SEQ ID NO.2;
[0019] B2) a cDNA nucleic acid molecule or a DNA nucleic acid molecule that hybridizes with the cDNA nucleic acid molecule or the DNA nucleic acid molecule defined in B1) and encodes a protein having the same function;
[0020] B3) an expression cassette containing the nucleic acid molecule described in B1) and / or B2);
[0021] B4) A recombinant vector containing the nucleic acid molecule described in B1) and / or B2), or a recombinant vector containing the expression cassette described in B3).
[0022] On the other hand, the present application also provides an engineered bacterium for preparing difucosyllactose, wherein the engineered bacterium expresses ɑ-1,2-glycosyltransferase and / or ɑ-1,3-glycosyltransferase, wherein the ɑ-1,2-glycosyltransferase is SAMT, and the ɑ-1,3-glycosyltransferase is fut3Bc.
[0023] Further, the amino acid sequence of SAMT includes SEQ ID NO.11 or an amino acid sequence having at least 98% identity with SEQ ID NO.11; preferably, the nucleotide sequence encoding SAMT includes SEQ ID NO.1 or a nucleotide sequence having at least 98% identity with SEQ ID NO.1;
[0024] And / or, the amino acid of fut3Bc includes SEQ ID NO.12 or an amino acid sequence having at least 98% identity with SEQ ID NO.12; preferably, the nucleotide sequence encoding fut3Bc is SEQ ID NO.2 or a nucleotide sequence having at least 98% identity with SEQ ID NO.2.
[0025] Preferably, the amino acid sequence of SAMT comprises SEQ ID NO.11 or an amino acid sequence having at least 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% sequence identity with SEQ ID NO.11.
[0026] Preferably, the nucleotide sequence encoding SAMT comprises SEQ ID NO.1 or a nucleotide sequence having at least 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identity with SEQ ID NO.1.
[0027] Preferably, the amino acids of fut3Bc include SEQ ID NO.12 or an amino acid sequence that is at least 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identical to SEQ ID NO.12.
[0028] Preferably, the nucleotide sequence encoding fut3Bc is SEQ ID NO.2 or a nucleotide sequence having at least 98%, 99%, 99.1%, 99.2%, 99.3%, 99.4%, 99.5%, 99.6%, 99.7%, 99.8% or 99.9% identity with SEQ ID NO.2.
[0029] Furthermore, the engineered bacteria include the biological material.
[0030] Furthermore, the engineered bacteria is selected from one or more of Corynebacterium glutamicum, Bacillus subtilis, Escherichia coli, and Saccharomyces cerevisiae; preferably, the engineered bacteria is Escherichia coli.
[0031] In a preferred embodiment, the Escherichia coli may be Escherichia coli (E. coli) BL21 (DE3).
[0032] Furthermore, the engineered bacteria also include any one or more of the following modifications:
[0033] A1) silencing and / or attenuating the gene encoding UDP-glucose lipid carrier transferase and / or the gene encoding β-galactosidase;
[0034] A2) the activity of mannose 1-guanylate transferase, phosphomannosylase, GDP-D-mannose-4,6-dehydratase, GDP-fucose synthase and / or mannose 6-phosphate isomerase is increased;
[0035] A3) The activity of RcsAB regulatory proteins is enhanced.
[0036] Among them, the way to achieve silencing and / or weakening can be knocking out the gene, and the way to achieve activity enhancement can be expressing or overexpressing the gene.
[0037] Furthermore, the transformation includes expression or overexpression on the genome and / or plasmid.
[0038] Furthermore, the engineered bacteria also include any one or more of the following modifications:
[0039] A1) knocking out the gene encoding UDP-glucose lipid carrier transferase (WcaJ) and / or the gene encoding β-galactosidase (LacZ);
[0040] A2) increasing the expression of mannose 1-guanylate transferase (manC), phosphomannosylase (manB), GDP-D-mannose-4,6-dehydratase (gmd), GDP-fucose synthase (wcaG) and / or mannose 6-phosphate isomerase (manA); preferably, the method for increasing the expression comprises replacing the native promoter with a strong promoter; more preferably, the strong promoter is P J23119 and / or P tac70 ;
[0041] A3) expressing SAMT; preferably, the expression includes free expression and / or integrated expression; more preferably, SAMT is integrated and expressed at the arsB and / or ldhA sites; more preferably, a strong promoter is used to initiate the expression, and the strong promoter is P J23119 ;
[0042] A4) expressing fut3Bc; preferably, the expression includes free expression and / or integrated expression; more preferably, fut3Bc is integrated and expressed at the poxB site; more preferably, a strong promoter is used to initiate the expression, and the strong promoter is P J23119 ;
[0043] A5) integrating and expressing manA at the xylB site; preferably, using a strong promoter to drive expression, the strong promoter is P tac70 ;
[0044] A6) integrating and expressing RcsAB at the galU site; preferably, using a strong promoter to drive expression, the strong promoter is P tac70 .
[0045] Among them, in A1), the NCBI sequence number of UDP-glucose lipid carrier transferase (WcaJ) is NP_416551.1, and the NCBI sequence number of β-galactosidase (LacZ) is NP_414878.1.
[0046] A2), the nucleotide sequence of mannose 6-phosphate isomerase (manA) is shown in SEQ ID No.3.
[0047] The nucleotide sequence of mannose 1-guanylate transferase (manC) is shown in SEQ ID No.4.
[0048] The nucleotide sequence of phosphomannosidase (manB) is shown in SEQ ID No.5.
[0049] The nucleotide sequence of GDP-D-mannose-4,6-dehydratase (gmd) is shown in SEQ ID No.6.
[0050] The nucleotide sequence of GDP-fucose synthase (wcaG) is shown in SEQ ID No.7.
[0051] Preferably, the strong promoter for increasing mannose 1-guanylate transferase, phosphomannosylase, GDP-D-mannose-4,6-dehydratase, and GDP-fucose synthase is P J23119 , increasing the promoter of mannose 6-phosphate isomerase to P tac70 .
[0052] Strong promoter P J23119 The nucleotide sequence is shown in SEQ ID NO.9.
[0053] Strong promoter P tac70 The nucleotide sequence is shown in SEQ ID NO.10.
[0054] A3), the expression includes free expression and integrated expression.
[0055] Preferably, the integration expression sites of SAMT include arsB and ldhA, the NCBI sequence number of the arsB site is EKR7607719.1, and the NCBI sequence number of the ldhA site is END6437385.1.
[0056] Preferably, the vector for free expression of SAMT is pCDFDuet plasmid.
[0057] A4), the expression includes free expression and integrated expression.
[0058] Preferably, the integration expression site of fut3Bc includes a poxB site, and the NCBI sequence number of the poxB site is WP_088537984.1.
[0059] Preferably, the vector for free expression of fut3Bc is a pETDuet plasmid.
[0060] A5), the NCBI sequence number of the xylB site is WP_112028713.1.
[0061] A6), the nucleotide sequence of RcsAB is shown in SEQ ID No.8, and the NCBI sequence number of the galU site is WP_262018987.1.
[0062] Preferably, CBGW is expressed in the engineered bacteria.
[0063] In a preferred embodiment, the engineered bacteria also include a recombinant plasmid pRSF-CBGW.
[0064] In a preferred embodiment, the engineered bacteria include plasmids for free expression of fut3Bc and SAMT, and the genes encoding UDP-glucose lipid carrier transferase and β-galactosidase are knocked out, the expression of manC-manB, gmd-wcaG and manA gene clusters is increased, SAMT is integrated and expressed at the arsB and / or ldhA sites, fut3Bc is integrated and expressed at the poxB site, and RcsAB is integrated and expressed at the galU site.
[0065] It is understandable to those skilled in the art that the existing gene editing technology can be used to complete the construction and transformation of the engineered bacteria of the present application.
[0066] In an optional embodiment, the vector and the engineered bacteria may contain a resistance screening marker gene, and those skilled in the art may make a selection according to actual conditions. The present application does not impose a mandatory limitation on the resistance screening marker gene.
[0067] On the other hand, the present application also provides a whole-cell catalyst containing the engineered bacteria.
[0068] On the other hand, the present application also provides the use of the engineered bacteria or the whole-cell catalyst in the preparation of difucosyllactose and / or products containing difucosyllactose.
[0069] On the other hand, the present application also provides a method for preparing difucosyllactose, the method comprising: using the engineered bacteria to ferment and prepare difucosyllactose.
[0070] Those skilled in the art can use the engineered bacteria of the present application to prepare difucosyllactose using a general method.
[0071] In a preferred embodiment, the method comprises: picking a single colony in a culture medium, culturing at 37-38°C overnight to obtain a seed solution, inoculating 1%-5% of the colony in a glycerol quantitative culture medium, adding yeast extract, and shaking and culturing at 37-38°C until the OD 600 When the concentration is 2.4-2.6, IPTG is added to induce recombinant expression, and lactose is injected as a substrate to produce difucosyllactose. The culture temperature is changed to 25-26°C, and the culture is continued for 70-100 hours to obtain difucosyllactose.
[0072] Preferably,
[0073] The method comprises: picking a single colony in a culture medium, culturing at 37°C overnight to obtain a seed solution, inoculating in a glycerol quantitative culture medium with an inoculum of 2.5% and adding 5 g / L yeast extract, and culturing at 37°C with shaking until the OD 600 At 2.4-2.6, IPTG with a final concentration of 0.1 mM was added to induce recombinant expression, and lactose with a final concentration of 5 g / L was injected as a substrate to produce difucosyllactose. The culture temperature was changed to 25°C and the culture was continued for 72 hours to obtain difucosyllactose.
[0074] On the other hand, the present application also provides a method for increasing the production of difucosyllactose, the method comprising increasing the expression of ɑ-1,2-glycosyltransferase and / or ɑ-1,3-glycosyltransferase, the ɑ-1,2-glycosyltransferase being SAMT, and the ɑ-1,3-glycosyltransferase being fut3Bc.
[0075] Further, the amino acid sequence of SAMT includes SEQ ID NO.11 or an amino acid sequence having at least 98% identity with SEQ ID NO.11; preferably, the nucleotide sequence encoding SAMT includes SEQ ID NO.1 or a nucleotide sequence having at least 98% identity with SEQ ID NO.1;
[0076] And / or, the amino acid of fut3Bc includes SEQ ID NO.12 or an amino acid sequence having at least 98% identity with SEQ ID NO.12; preferably, the nucleotide sequence encoding fut3Bc is SEQ ID NO.2 or a nucleotide sequence having at least 98% identity with SEQ ID NO.2.
[0077] The present invention has the following beneficial effects:
[0078] The present invention uses SAMT and fut3Bc for the first time to synthesize DFL using lactose as a substrate, providing two new enzymes and a new enzyme combination for the synthesis of DFL. The α-1,2-glycosyltransferase encoding gene SAMT from Azospirillum lipoferum used in the present invention has a strict and efficient utilization ability for lactose and has no ability to recognize 3-fucosyllactose; while the α-1,3-glycosyltransferase encoding gene fut3Bc of Neobacillus cucumis can use lactose as a substrate to synthesize DFL. Therefore, the two can synergistically increase the yield of DFL, providing a new idea for the transformation of DFL-related engineering bacteria.
[0079] The present invention constructs a new DFL engineering bacterium, wherein the engineering bacterium uses Escherichia coli as the starting strain, knocks out the UDP-glucose lipid carrier transferase encoding gene and the β-galactosidase encoding gene in the genome of the starting strain; J23119 Promote the expression of manC, manB, gmd and wcaG genes on the genome of the starting strain; tac70 The expression of gene manA in the genome was strengthened, and the expression of SAMT, fut3Bc and the gene RcsAB that positively regulates the GDP-fucose pathway were integrated. The resulting engineered bacteria, namely the recombinant strain CS-10, can efficiently produce DFL. The DFL yield in a 5L fermenter reached 53.15g / L in 90h, which is significantly higher than the existing technology. BRIEF DESCRIPTION OF THE DRAWINGS
[0080] The drawings described herein are used to provide a further understanding of the present application and constitute a part of the present application. The illustrative embodiments of the present application and their descriptions are used to explain the present application and do not constitute an improper limitation on the present application. In the drawings:
[0081] Figure 1 This is the fermentation optimization result diagram of strains CS-1~2 and CF-1~2, where nd means no target product was detected;
[0082] Figure 2The results of the fermentation of two plasmids and three plasmids after adding 5 g / L yeast extract, where nd means no target product was detected;
[0083] Figure 3 This is a diagram of the fermentation results of DFL integrating SAMT and fut3Bc engineered bacteria;
[0084] Figure 4 The results of testing the catalytic preference of SAMT and Fut3Bc using 2′-fucosyllactose and 3-fucosyllactose as substrates, where nd means no target product was detected;
[0085] Figure 5 It is a comparison chart of the fermentation effects of the integrated genes manA and RcsAB;
[0086] Figure 6 The mass spectrometry identification results of DFL in the fermentation broth of engineered bacteria CS-10 and CF-10, where a is the DFL standard, b is the result of the fermentation broth of strain CF-10, and c is the result of the fermentation broth of strain CS-10. DETAILED DESCRIPTION
[0087] Technical terms:
[0088] Identity: refers to the degree of similarity between the nucleotide sequences of two nucleic acid molecules or between the amino acid sequences of two protein molecules in molecular evolution research.
[0089] Recombination: Broadly speaking, any gene exchange process that causes genotype changes is called recombination.
[0090] Recombinant microorganism (recombinant bacteria): a fungal cell strain in which exogenous genes are efficiently expressed using genetic engineering methods.
[0091] Whole-cell catalyst: Whole-cell biocatalysis refers to the process of using a complete biological organism (i.e., whole cell, tissue, or even individual) as a catalyst for chemical transformation. The corresponding complete biological organism involved in the catalytic process is the whole-cell catalyst.
[0092] In order to more clearly explain the overall concept of the present application, the following is described in detail in conjunction with the accompanying drawings of the specification by way of embodiment. In the following description, a large number of specific details are provided to provide a more thorough understanding of the present invention. However, it is obvious to those skilled in the art that the present invention can be implemented without one or more of these details. In other examples, in order to avoid confusion with the present invention, some technical features well known in the art are not described.
[0093] If the specific conditions are not specified in the examples, the conventional conditions or the conditions recommended by the manufacturer are used. The plasmids, endonucleases, PCR enzymes, column DNA extraction kits and DNA gel recovery kits used in the following examples are commercial products, and the specific operations are carried out according to the kit instructions.
[0094] Unless otherwise stated, the experimental methods, detection methods, and preparation methods disclosed in the present invention all adopt conventional techniques in the field of molecular biology, biochemistry, chromatin structure and analysis, analytical chemistry, cell culture, recombinant DNA technology, and related fields, and can be specifically carried out according to Molecular Cloning: A Laboratory Manual (Fourth Edition).
[0095] In addition, the "water" mentioned in the present invention includes any feasible water that can be used in the art, such as deionized water, distilled water, ion exchange water, double distilled water, high-purity water, and purified water.
[0096] In the following examples, unless otherwise specified, % means wt %, i.e. weight percentage.
[0097] Fermentation medium for difucosyllactose Description:
[0098] LB liquid medium (seed medium): peptone 10 g / L, yeast extract 5 g / L, sodium chloride 10 g / L.
[0099] LB solid medium: peptone 10 g / L, yeast extract 5 g / L, sodium chloride 10 g / L, agar powder 15 g / L.
[0100] Glycerol quantitative medium (fermentation medium): 30g / L glycerol, 5g / L yeast extract, 13.5g / L potassium dihydrogen phosphate, 4.0g / L diammonium hydrogen phosphate, 1.7g / L citric acid, 1.4g / L magnesium sulfate heptahydrate, 10ml / L 10g / L ferrous sulfate, 2.25g / L zinc sulfate heptahydrate, 1.0g / L anhydrous copper sulfate, 0.35g / L manganese sulfate monohydrate, 0.23g / L sodium borate decahydrate, 0.11g / L ammonium molybdate, 2.0g / L calcium chloride dihydrate.
[0101] Detection method of difucosyllactose (HPLC):
[0102] Detector: differential detector; mobile phase: 0.5mmol / L, H2SO4; flow rate: 0.6mL / min; chromatographic column: CarbohydrateAnalysis (Rezex ROA-organic acid H + (8%)); column temperature: 60°C; injection volume: 10 μL;
[0103] Mass spectrometry detection parameters:
[0104] Mass spectrometry analysis was performed using a MALDI SYNAPT Q-TOF mass spectrometer (Waters, Milford, MA, USA) with capillary: 3.5 kV; cone, 20 V; source block temperature, 100°C; desolvation temperature, 400°C; desolvation gas flow rate: 700 L / h; cone gas flow rate: 50 L / h; collision energy: 6 eV; mass range (m / z): 50-1000; detector voltage: 2000 V.
[0105] The strains and plasmid information involved in the following examples are as follows
[0106]
[0107]
[0108]
[0109] Example 1
[0110] The ɑ-1,2-glycosyltransferase encoding gene SAMT (amino acid sequence SEQ ID NO.11) from Azospirillum lipoferum was codon optimized, and the optimized nucleotide sequence was shown in SEQ ID NO.1. The gene shown in SEQ ID NO.1 was constructed into the No. 2 multiple cloning site (MCS2) of the plasmid pETDuet to obtain pCDF-SAMT. The sequencing was delivered to Suzhou Jinweizhi Biotechnology Co., Ltd.
[0111] The ɑ-1,3-glycosyltransferase encoding gene fut3Bc (amino acid sequence SEQ ID NO.12) from Neobacillus cucumis was codon optimized, and the optimized nucleotide sequence was shown in SEQ ID NO.2. The gene shown in SEQ ID NO.2 was constructed into the No. 2 multiple cloning site (MCS2) of the plasmid pETDuet to obtain pET-fut3Bc. The sequencing and construction of pET-fut3Bc were delivered to Suzhou Jinweizhi Biotechnology Co., Ltd.
[0112] The construction of plasmid pRSF-CBGW is described in patent document with publication number CN114874964A.
[0113] Example 2
[0114] The gene wcaJ encoding UDP-glucose lipid carrier transferase WcaJ (NCBI sequence number NP_416551.1) and the gene lacZ encoding β-galactosidase LacZ (NCBI sequence number NP_414878.1) in Escherichia coli BL21 were knocked out. The gene knockout method is specifically referred to the patent with publication number CN110804577A, and the recombinant bacteria BWL were obtained.
[0115] Using the CRISPR-Cas9 gene editing system, the native promoters of the gene clusters manC-manB and gmd-wcaG in the genome of the recombinant bacterium BWL were replaced with the constitutive promoter P J23119 (The sequence is SEQ ID NO.9), the replacement method and primer information are specifically referred to the patent publication number CN114874964A, and the recombinant bacteria B2P were obtained.
[0116] The native promoter of gene manA in the genome of recombinant bacteria B2P was replaced with the constitutive promoter P using the pEcCpf1 / pcrEG gene editing system. tac70 (The sequence is SEQ ID NO.10), and the recombinant bacterium B3P was obtained.
[0117] The recombinant bacterium B3P was integrated with a P at the arsB site (NCBI sequence number: EKR7607719.1). J23119 The expression of SAMT was initiated to obtain strain B4P; the ldhA site (NCBI sequence number END6437385.1) with P J23119 The expression of SAMT was initiated to obtain strain B5P; the poxB locus (NCBI sequence number WP_088537984.1) with P J23119 The expression of fut3Bc was initiated to obtain strain B6P. The recombinant strain B6P genome was integrated with P at the xylB site. tac70 The expression of manA was initiated to obtain strain B7P; the galU site of the recombinant strain B6P genome was integrated with P tac70 The expression of RcsAB (the nucleotide sequence of RcsAB is shown in SEQ ID No. 8) was initiated to obtain strain B8P. The strains and their corresponding genotypes are shown in Table 2.
[0118] Among them, the nucleotide / base sequences of the genes manA, manC, manB, gmd, and wcaG are shown as SEQ ID No.3, SEQ ID No.4, SEQ ID No.5, SEQ ID No.6, and SEQ ID No.7, respectively.
[0119] The strain construction operation is as follows:
[0120] Using the E. coli BL21 genome as a template, primers arsB-UP-F / R and arsB-DH-F / R were used to amplify the upper and lower target fragments UP and Down of the arsB site by PCR. Using the plasmid pCDF-SAMT constructed in Example 1 as a template, primers SAMT-J23-F / R were used to amplify P J23119 -SAMT-T7 term fragment. J23119 -SAMT-T7term three fragments were assembled and constructed using primers arsB-over-F / R, and the final fragment UP-P was obtained by gel recovery. J23119 -SAMT-T7 term-Down was used as donor template.
[0121] Using the E. coli BL21 genome as a template, primers ldhA-UP-F / R and ldhA-DH-F / R were used to amplify the upper and lower target fragments UP and Down of the ldhA site by PCR. J23119 -SAMT-T7 term fragments were assembled and the donor template was obtained by gel recovery;
[0122] Using the E. coli BL21 genome as a template, primers PoxB-UP-F / R and PoxB-DH-F / R were used to amplify the upper and lower target fragments UP and Down of the poxB site by PCR. Using the plasmid pET-fut3Bc constructed in Example 1 as a template, primers Fut3Bc-J23-F / R were used to amplify P J23119 -fut3Bc-T7 term fragment. J23119 -fut3Bc-T7 term three fragments were assembled and constructed using primers PoxB-OVER-F / R, and the final fragment UP-P was obtained by gel recovery. J23119 -fut3Bc-T7 term-Down was used as donor template.
[0123] Using the E. coli BL21 genome as a template, primers XylB-UP-F / R and XylB-DH-F / R were used to amplify the upper and lower target fragments UP and Down of the xylB site (NCBI sequence number WP_112028713.1) by PCR. At the same time, primers ManA-Tac70-F / R were used to amplify P tac70 -manA-T7 term fragment; assembled and constructed by PCR using primers XylB-OVER-F / R, and the donor template was obtained by gel recovery.
[0124] Using the E. coli BL21 genome as a template, primers GalU-UP-F / R and GalU-DH-F / R were used to amplify the upper and lower target fragments UP and Down of the galU site (NCBI sequence number WP_262018987.1) by PCR, respectively; using the plasmid pET-AB-SAMT in publication number CN116769808 A as a template, primers RCSAB-F / R were used to amplify P tac70 -RcsAB-T7 term fragment was assembled and constructed using primers GalU-OVER-F / R, and the donor template was obtained by gel recovery.
[0125] N23 sequences with corresponding recognition regions were found at the arsB, ldhA and pox sites to identify and locate the cutting of arsB, ldhA and pox to integrate SAMT and fut3Bc respectively. Using the original pEcgRNA plasmid as a template, pTarget-F-arsB, pTarget-F-ldhA and pTarget-F-poxB were obtained by primers arsB-N23-F / R, ldhA-N23-F / R and poxB-N23-F / R loop P. The obtained pTarget-F (800 ng) specific site plasmid and donor template (200 ng) were electroporated into the electroporation competent target strain carrying the pEcCpf1 plasmid. The voltage of the electroporator was set to 2.5 kv (2 mm electroporation cup). After electroporation, 900 μL of pre-cooled LB on ice was immediately added. After incubation at 37°C for 1 hour, the plate was coated with kanamycin (Kan) and spectinomycin (Spc) double-resistance plates and cultured in a 37°C oven overnight. After successful sequencing, the recombinant strain B6P carrying SAMT and fut3Bc as well as strains BWL, B2P, B3P, B4P, and B5P were obtained.
[0126] The N23 sequence with the corresponding recognition region was found at the xylB and galU sites to identify and position the cutting of xylB and galU to integrate manA and RcsAB respectively. Using the original pEcgRNA plasmid as a template, pTarget-F-xylB and pTarget-F-galU were obtained by primers xylB-N23-F / R and galU-N23-F / R loop P. The obtained pTarget-F (800ng) specific site plasmid and donor template (200ng) were electroporated into the target strain with pEcCpf1 plasmid. The voltage of the electroporator was set to 2.5kv (2mm electroporation cup). After electroporation, 900μL LB pre-cooled on ice was added immediately. After incubation at 37℃ for 1h, kanamycin (Kan) and spectinomycin (Spc) double-resistance plates were coated and cultured in a 37℃ oven overnight. After successful sequencing, recombinant strains B7P and B8P carrying manA / RcsAB were obtained.
[0127] The successfully verified bacteria were inoculated into a 4 mL LB test tube containing rhamnose at a final concentration of 10 mM and 1‰ kanamycin and cultured at 37°C overnight. After the end, they were streaked on a solid LB plate (containing kanamycin) and cultured at 37°C; after a single colony grew on the plate, they were streaked on an LB plate containing kanamycin or kanamycin and spectinomycin, respectively, and cultured at 37°C. Bacteria that grow on a plate containing kanamycin but do not grow on a plate containing kanamycin and spectinomycin have successfully removed the pTarget-F plasmid; then the single colony was further inoculated into an LB liquid culture medium containing 5 g / L glucose and cultured at 37°C, 200 rpm for 10-12 hours. After that, about 10 μL of the bacterial solution was streaked on an LB plate containing 5 g / L glucose and 10 g / L sucrose and cultured at 37°C for 10-12 hours. Single colonies were randomly selected and streaked on LB plates without antibiotics and LB plates containing kanamycin. The bacteria that grew on the plates without antibiotics and did not grow on the LB plates containing kanamycin were the hosts from which the plasmid was finally successfully removed.
[0128] The primer sequences used in the above construction process are shown in Table 1.
[0129] Table 1 Primer sequences used to construct recombinant engineering bacteria
[0130]
[0131]
[0132]
[0133] Example 3
[0134] The recombinant plasmid pRSF-CBGW (i.e., pRSF-manC-manB (MCS1)-gmd-wcaG (MCS2)), pET-fut3Bc, and pCD-SAMT constructed in Example 1 were transferred into the strain BWL constructed in Example 2 to obtain the recombinant bacterium CS-1. As a control, pRSF-CBGW, pET-fut3Bc, and pCD-fucT2 were transferred into the strain BWL to obtain the recombinant bacterium CF-1. Plasmid pCD-fucT2 is derived from patent CN 118064340A. Specific strain plasmid combination information is shown in Table 2.
[0135] The recombinant plasmid combination pRSF-CBGW, pET-fut3Bc and pCD-SAMT or pET-fut3Bc and pCD-SAMT was transferred into the recombinant engineering strains B2P-B6P, and the information of the obtained recombinant bacteria is shown in Table 2. As a control, pCD-SAMT was replaced with pCD-fucT2 and transferred into the recombinant engineering strains B2P, B3P and B4P in the same three-plasmid or two-plasmid form as mentioned above, and strains CS-2, CF-2, CS-3, CS-4, CF-3, CF-4, CS-5, CS-6, CF-5, CF-6, CS-7, CF-7, CS-8, and CF-8 were obtained.
[0136] In the production process of DFL, ɑ-1,2-fucosyltransferase and ɑ-1,3-glycosyltransferase are required to cooperate in in vivo catalysis. Therefore, it is necessary to verify the verification ability of potential substrates. The plasmids pCD-SAMT, pET-fut3Bc and pCD-fucT2 were respectively transferred into strain B3P to obtain strains D1, D2 and D3. The strains and their genotypes are shown in Table 2.
[0137] In order to further improve the in vivo accumulation capacity of GDP-fucose, in this example, by introducing the plasmid combination pET-fut3Bc and pCD-SAMT into B7P and B8P, pCD-SAMT was replaced with pCD-fucT2 as a control to obtain strains CS-9, CF-9, CS-10, and CF-10. The specific strain information is shown in Table 2.
[0138] The fermentation method of the above-mentioned obtained strain is as follows:
[0139] Shake flask fermentation of strains containing three plasmids: pick a single colony in 4 mL of liquid LB medium containing 1‰ ampicillin, streptomycin, and kanamycin, place it in a shaker at 37°C overnight, take 1 mL of the culture solution and inoculate it into 25 mL of glycerol quantitative medium containing 1‰ ampicillin and kanamycin antibiotics and add 5 g / L yeast extract, and shake and culture it in a shaker at 37°C until OD 600 At 2.4-2.6, IPTG with a final concentration of 0.1 mM was added to induce recombinant expression, and 5 g / L lactose was injected as a substrate to generate difucosyllactose. The culture temperature was changed to 25°C, and the culture was continued for 72 hours before the fermentation liquid was taken for HPLC detection.
[0140] Shake flask fermentation of strains containing two plasmids: pick a single colony in 4 mL of liquid LB medium with 1‰ ampicillin and streptomycin antibiotics, place it in a shaker at 37°C overnight, take 1 mL of the culture solution and inoculate it into 25 mL of glycerol quantitative medium containing 1‰ ampicillin and kanamycin antibiotics and add 5 g / L yeast extract, and shake and culture it in a shaker at 37°C until OD 600At 2.4-2.6, IPTG with a final concentration of 0.1 mM was added to induce recombinant expression, and 5 g / L lactose was injected as a substrate to generate difucosyllactose. The culture temperature was changed to 25°C, and the culture was continued for 72 hours before the fermentation liquid was taken for HPLC detection.
[0141] Shake flask fermentation of strains containing a single plasmid: pick a single colony in 4 mL of liquid LB medium with 1‰ ampicillin or streptomycin antibiotics, place it in a shaker at 37°C overnight, take 1 mL of the culture solution and inoculate it into 25 mL of glycerol quantitative medium containing 1‰ ampicillin antibiotics and add 5 g / L yeast extract, and shake and culture it in a shaker at 37°C until OD 600 The pH value was between 0.6 and 0.8, and then IPTG with a final concentration of 0.1 mM was added to induce recombinant expression, and 5 g / L lactose with a final concentration was injected as a substrate to generate difucosyllactose. The culture temperature was changed to 25°C, and the culture was continued for 72 hours before the fermentation broth was taken for HPLC detection.
[0142] HPLC was used to detect the formation of difucosyllactose and 2'-fucosyllactose and the fermentation results (OD 600 ), the test results are shown in Table 2 and Figure 1-5 As shown, the mass spectrometry results of strains CS-10 and CF-10 are as follows Figure 6 (where a is the DFL standard, b is the CS-10 fermentation result, and c is the CF-10 fermentation result) As shown, the fermentation broth samples of strains CS-10 and CF-10 both showed the target molecular weight consistent with the DFL standard.
[0143] Table 2 Engineering strains and plasmid information for difucosyllactose production
[0144]
[0145]
[0146] As shown in Table 2 and Figure 1 The results showed that, unlike CS-1, the CS-2 genome carries an integrated constitutive promoter P J23119 , strengthened the expression of CBGW, a key gene in the GDP-fucose pathway, and significantly increased the DFL production of CS-2. Moreover, the only difference between CF-2 and CS-2 is the different α-1,2-glycosyltransferase expression plasmids transferred into them, proving that compared with fucT2, SAMT and fut3Bc can jointly improve the ability of engineered bacteria to produce DFL by fermentation.
[0147] As shown in Table 2 and Figure 4The results showed that α-1,2-fucosyltransferases SAMT and fucT2 could not synthesize DFL using 3-FL as a substrate, while Fut3Bc could use 2′-FL as a substrate to synthesize 2.96 g / L of DFL.
[0148] From Table 2 and Figure 2 , Figure 3 , Figure 5 The results showed that the production of difucosyllactose in shake flask fermentation of strains CS-9, CS-10, CF-9 and CF-10 was 8.22 g / L, 8.34 g / L, 7.38 g / L and 7.58 g / L, respectively.
[0149] Example 4
[0150] To further verify the production effect of strain CS-10 constructed in Example 3 in a 5L fermenter, strain CS-10 was inoculated into 150mL of fermentation medium (containing 5g / L yeast extract) to obtain seed liquid, and the seed liquid was inoculated into a 5L fermenter containing 1.5L glycerol quantitative medium (glycerol 30g / L) at an inoculation ratio of 10% (v / v), and the dissolved oxygen was set to 30%, the growth temperature was 37°C, the stirring speed was 800rpm, the ventilation volume was 2vvm, and the pH was 6.6±0.05. The pH during the growth process was regulated with ammonia water to maintain the pH stability of the entire fermentation process; when the OD of the strain in the tank was 600 When the cells grow to 16-20, slowly add lactose at a final concentration of 1 g / L, and slowly lower the temperature to 25°C. During this period, check the consumption of lactose and glycerol at irregular intervals. Supplement lactose (200 g / L lactose) and glycerol (600 g / L glycerol contains 20 g / L magnesium sulfate heptahydrate and 0.2 g / L thiamine) to maintain the concentration of lactose and glycerol in the fermentation system at 1-5 g / L. The whole fermentation time is not less than 60 hours.
[0151] At the final fermentation time of 90 h, the difucosyllactose production of strain CS-10 reached 53.15 g / L, which is the highest production capacity reported so far.
[0152] The above is only an embodiment of the present application and is not intended to limit the present application. For those skilled in the art, the present application may have various changes and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application should be included in the scope of the claims of the present application.
Claims
1. Use of ɑ-1,2-glycosyltransferase and / or ɑ-1,3-glycosyltransferase in preparing difucosyllactose and / or increasing the yield of difucosyllactose, characterized in that: The ɑ-1,2-glycosyltransferase comprises SEQ ID NO.11 or an amino acid sequence having at least 98% identity with SEQ ID NO.11, and the ɑ-1,3-glycosyltransferase comprises SEQ ID NO.12 or an amino acid sequence having at least 98% identity with SEQ ID NO.
12.
2. Biomaterial, characterized in that A biological material related to the α-1,2-glycosyltransferase and / or α-1,3-glycosyltransferase according to claim 1, wherein the biological material comprises any one of the following: B1) the biological material comprises a cDNA nucleic acid molecule or a DNA nucleic acid molecule of SEQ ID NO.1 and / or SEQ ID NO.2; B2) a cDNA nucleic acid molecule or a DNA nucleic acid molecule that hybridizes with the cDNA nucleic acid molecule or the DNA nucleic acid molecule defined in B1) and encodes a protein having the same function; B3) an expression cassette containing the nucleic acid molecule described in B1) and / or B2); B4) A recombinant vector containing the nucleic acid molecule described in B1) and / or B2), or a recombinant vector containing the expression cassette described in B3).
3. An engineered bacterium for preparing difucosyllactose, characterized in that: The engineered bacteria include expressing ɑ-1,2-glycosyltransferase and / or ɑ-1,3-glycosyltransferase, wherein the ɑ-1,2-glycosyltransferase comprises SEQ ID NO.11 or an amino acid sequence having at least 98% identity with SEQ ID NO.11, and the amino acid of the ɑ-1,3-glycosyltransferase comprises SEQ ID NO.12 or an amino acid sequence having at least 98% identity with SEQ ID NO.
12.
4. The engineered bacteria according to claim 3, characterized in that The engineered bacteria include the biological material according to claim 2.
5. The engineered bacteria according to claim 3 or 4, characterized in that: The engineered bacteria is selected from one or more of Corynebacterium glutamicum, Bacillus subtilis, Escherichia coli, and Saccharomyces cerevisiae; preferably, the engineered bacteria is Escherichia coli.
6. The engineered bacteria according to claim 3 or 4, characterized in that: The engineered bacteria may also include any one or more of the following modifications: A1) silencing and / or attenuating the gene encoding UDP-glucose lipid carrier transferase and / or the gene encoding β-galactosidase; A2) increasing the activity of mannose 1-guanylate transferase, phosphomannosylase, GDP-D-mannose-4,6-dehydratase, GDP-fucose synthase and / or mannose 6-phosphate isomerase; A3) The activity of RcsAB regulatory proteins is enhanced.
7. The engineered bacteria according to claim 6, characterized in that The transformation includes expression or overexpression on genome and / or plasmid.
8. A whole-cell catalyst comprising the engineered bacteria as claimed in any one of claims 3 to 7.
9. Use of the biomaterial according to claim 2, the engineered bacteria according to any one of claims 3 to 7, or the whole-cell catalyst according to claim 8 in the preparation of difucosyllactose and / or products containing difucosyllactose.
10. A method for preparing difucosyllactose, characterized in that: The method comprises: preparing difucosyllactose by fermentation using the engineered bacteria as described in any one of claims 3 to 7.
Citation Information
Cited By
Alpha-1, 3-glycosyltransferase mutant, recombinant microorganism and application
CN122427887A
